Sleep, Metabolism, and the Forgotten Amino Acid

Evidence Review

Sleep Quality — RCT Evidence

Bannai et al. (2012, PMID 22529837) conducted a randomized, double-blind, placebo-controlled crossover trial in 10 healthy adults who were partially sleep-restricted (6 hours/night for 3 nights). Subjects receiving 3 g glycine before bed reported significantly less fatigue, daytime sleepiness, and improved psychomotor vigilance scores compared to placebo. The effect size was clinically meaningful: a 14% reduction in fatigue on a visual analog scale and measurable improvements on the Karolinska Sleepiness Scale. Limitations include the small sample size and short duration.

The companion review by the same group (Bannai & Kawai, 2012, PMID 22293292) describes mechanistic studies showing that glycine decreases core body temperature via peripheral vasodilation and promotes sleep onset through NMDA receptor modulation in the suprachiasmatic nucleus. Both subjective and polysomnographic data support glycine's sleep-enhancing properties.

Metabolic Syndrome — Systematic Review

Imenshahidi & Hossenzadeh (2022, PMID 35013990) reviewed controlled studies of glycine supplementation on metabolic syndrome components including blood glucose, insulin resistance, hypertension, dyslipidemia, and obesity. They found consistent evidence across animal and human studies that glycine improves insulin sensitivity and fasting glucose, with human studies typically using 5–15 g/day doses. The review notes that low plasma glycine is a reliable biomarker for insulin resistance and that restoring glycine levels through diet or supplementation shows therapeutic promise. The authors call for larger, longer RCTs to establish optimal dosing.

Collagen Synthesis — In Vitro Mechanistic Study

De Paz-Lugo et al. (2018, PMID 30006659) demonstrated that incubating human articular chondrocytes with glycine at physiological-high concentrations (up to 1 mM above normal) produced a dose-dependent increase in collagen type II synthesis. The researchers calculated that the human body needs approximately 15–25 g/day of glycine for optimal collagen maintenance, far exceeding endogenous synthesis capacity (~3 g/day). This "conditional essentiality" of glycine is particularly relevant for aging populations and those with musculoskeletal conditions. Study limitation: in vitro results may not fully translate to in vivo clinical outcomes.

Anti-Inflammatory Mechanisms — 2023 Review

Aguayo-Cerón et al. (2023, PMID 37510995) provide a comprehensive mechanistic review of glycine's anti-inflammatory actions. Key findings: glycine activates strychnine-sensitive glycine receptors on leukocytes, hyperpolarizing the cell membrane and suppressing cytokine release. It also reduces NF-κB activation (a master switch for inflammatory gene expression) and modulates the NLRP3 inflammasome. The authors highlight glycine's favorable safety profile — it is one of the few amino acids with no established upper tolerable limit — and suggest it as a dietary adjunct for chronic inflammatory conditions. The review is narrative rather than meta-analytic, which limits certainty about effect sizes.

Glycine Deficiency and Metabolic Disease — Mechanistic Review

Alves et al. (2019, PMID 31208147) provide an in-depth analysis of glycine's metabolic roles and how deficiency contributes to insulin resistance, non-alcoholic fatty liver disease, and obesity. Plasma glycine levels are consistently 20–40% lower in obese and diabetic individuals compared to lean controls. The authors describe glycine's involvement in glutathione synthesis (the body's primary antioxidant), heme production, creatine synthesis, and one-carbon metabolism — illustrating why insufficient glycine has cascading effects across organ systems. Importantly, they note that restoring glycine in animal models of metabolic disease reverses several pathological changes, providing mechanistic justification for human supplementation trials.

Overall Evidence Assessment

The evidence for glycine's sleep benefits is moderate-strong (human RCT, plausible mechanism, replicable results) but limited by small sample sizes. The metabolic evidence is promising but relies more on observational correlations and in vitro/animal mechanistic data than large human RCTs. Collagen synthesis benefits are mechanistically sound and supported by the well-established role of glycine as a structural amino acid. Anti-inflammatory evidence is primarily mechanistic. Given glycine's excellent safety profile and low cost, the risk-benefit ratio for supplementation (3–10 g/day) is highly favorable for the populations most likely to benefit — those with poor sleep, metabolic concerns, or high physical activity demands.